| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/12/2013 | EP2601950A1 Cycloalkane carboxylic acid derivatives as CXCR3 receptor antagonists |
| 06/12/2013 | EP2601949A2 Pharmaceutical compositions |
| 06/12/2013 | EP2601948A1 Preparation for treatment of spinal cord injury |
| 06/12/2013 | EP2601947A1 Fixed-dose combination for treatment of helicobacter pylori associated diseases |
| 06/12/2013 | EP2601946A1 Treatment and prevention of diseases related to oxidative stress |
| 06/12/2013 | EP2601945A1 Inhibition of cis-platin induced ototoxicity |
| 06/12/2013 | EP2601944A1 Transdermal patch and method for augmenting adhesive strength thereof |
| 06/12/2013 | EP2601943A1 Anti-cancer composition containing chalcone compounds |
| 06/12/2013 | EP2601942A1 Novel combination of 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide and an acetylcholinesterase inhibitor, and pharmaceutical compositions containing same |
| 06/12/2013 | EP2601941A1 Beta-O/S/N fatty acid based compounds as antibacterial and antiprotozoal agents |
| 06/12/2013 | EP2601940A1 (4-mercapto-piperidin-4-yl)-aminoacetic acid derivatives, pharmaceutical compositions and uses thereof |
| 06/12/2013 | EP2601938A1 Pharmaceutical compositions for the treatment of Helicobacter pylori associated diseases |
| 06/12/2013 | EP2601937A1 Drinkable immediate release tablet made with direct compression of memantine or neramexane |
| 06/12/2013 | EP2601936A1 Compressed composition |
| 06/12/2013 | EP2601847A1 A nutraceutical compound for treating excess of weight |
| 06/12/2013 | EP2601844A1 Method of producing an extract enriched with trigonelline (TRIG) and/or chlorogenic acids (CQA), extract enriched with trigonelline (TRIG) and/or chlorogenic acids (CQA) and the use of same |
| 06/12/2013 | EP2601313A1 Prediction of hcv viral kinetics in interferon-free treatment |
| 06/12/2013 | EP2601294A1 Antisense oligonucleotide directed removal of proteolytic cleavage sites from proteins |
| 06/12/2013 | EP2601222A1 Glycolipid for treatment of ischemia reperfusion injury |
| 06/12/2013 | EP2601205A2 Guanine nucleotide derivatives for treating bacterial infections |
| 06/12/2013 | EP2601202A1 Bone-targeting bisphosphonate duplex drugs |
| 06/12/2013 | EP2601201A1 Process for preparation of novel 42-0-(heteroalkoxyalkyl) rapamycin compounds with anti-proliferative properties" |
| 06/12/2013 | EP2601200A2 Preparation of prasugrel hydrochloride |
| 06/12/2013 | EP2601198A1 Novel artemisinin-like derivatives with cytotoxic and anti-angiogenic properties |
| 06/12/2013 | EP2601197A1 Amino-iso-indole, amino-aza-iso-indole, amino-dihydroisoquinoline and amino-benzoxazine compounds as beta-secretase modulators and methods of use |
| 06/12/2013 | EP2601193A1 Compounds with antibacterial activity against clostridium |
| 06/12/2013 | EP2601192A1 Fused heterocyclic compounds |
| 06/12/2013 | EP2601191A2 Compounds and compositions for mitigating tissue damage and lethality |
| 06/12/2013 | EP2601189A1 N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides as inhibitors of plasma kallikrein |
| 06/12/2013 | EP2601188A1 Hepatitis c virus inhibitors |
| 06/12/2013 | EP2601187A1 Deuterated tandospirone derivatives as 5-ht1a receptor agonists |
| 06/12/2013 | EP2601186A2 4-(1h-indol-3-yl)-pyrimidines as alk inhibitors |
| 06/12/2013 | EP2601185A1 Derivatives of pyrazolophenyl-benzenesulfonamide compounds and use thereof as antitumor agents |
| 06/12/2013 | EP2601183A1 Coumarin-chalcones as anticancer agents |
| 06/12/2013 | EP2601181A1 Acid addition salts of the 2-[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]-(methyl)amino]ethoxy]-n-methyl-n-[3-(4-methylpiperazin-1-yl)cyclohexyl]acetamide and the use thereof as bradykinin b1 receptor antagonists |
| 06/12/2013 | EP2601180A1 Highly crystalline valsartan |
| 06/12/2013 | EP2601177A1 N-acylsulfonamide apoptosis promoters |
| 06/12/2013 | EP2601176A1 Novel salts of saxagrliptin with organic di-acids |
| 06/12/2013 | EP2601175A1 A novel crystalline compound comprising saxagliptin and phosphoric acid |
| 06/12/2013 | EP2601174A1 Substituted indole and azaindole oxoacetyl piperazinamide derivatives |
| 06/12/2013 | EP2601168A1 Treatment of mitochondrial diseases with vitamin k |
| 06/12/2013 | EP2600939A2 Polyphenol derivative composition and uses thereof as bactericide and fungicide |
| 06/12/2013 | EP2600927A1 Antimicrobial hydrochloric acid catheter lock solution and method of use |
| 06/12/2013 | EP2600901A2 Engineered nucleic acids and methods of use thereof |
| 06/12/2013 | EP2600897A2 Methods and compositions for the inhibition of fructokinase |
| 06/12/2013 | EP2600883A1 Composition comprising glutathione reductase and oxidized glutathione, and therapeutic uses thereof |
| 06/12/2013 | EP2600876A1 Combined drug delivery methods and apparatus |
| 06/12/2013 | EP2600875A1 Methods and pharmaceutical compositions for treating adverse or deleterious sequellae of traumatic brain injury |
| 06/12/2013 | EP2600874A1 Pyrimidine compounds that inhibit anaplastic lymphoma kinase |
| 06/12/2013 | EP2600873A1 Pharmaceutical compositions for terminating acute episodes of cardiac arrhythmia, restoring sinus rhythm, preventing recurrence of cardiac arrhythmia and/or maintaining normal sinus rhythm in mammals |
| 06/12/2013 | EP2600872A1 Fused-imidazoyl compounds useful as antimicrobial agents |
| 06/12/2013 | EP2600871A2 Methods for impairing the p53/hdm2 auto-regulatory loop in multiple myeloma development using mir-192, mir-194 and mir-215 |
| 06/12/2013 | EP2600870A2 Pump systems and methods for storing and dispensing a plurality of precisely measured unit-doses of imiquimod cream |
| 06/12/2013 | EP2600869A1 Combination of a pyrroloquinoline compound and a beta-lactam antimicrobial agent, mupirocin or chlorhexidine |
| 06/12/2013 | EP2600868A1 Combination of a pyrroloquinoline compound and an aminoglycodise antimicrobial agent |
| 06/12/2013 | EP2600867A1 Therapeutic combination comprising a parp-1 inhibitor and an anti-neoplastic agent |
| 06/12/2013 | EP2600866A1 Processes for preparing tubulysins |
| 06/12/2013 | EP2600865A1 Compound useful for the treatment of nonsense-mutation-mediated diseases and pharmaceutical composition comprising said compound |
| 06/12/2013 | EP2600864A2 Compositions and methods for treating inflammatory diseases |
| 06/12/2013 | EP2600863A2 Use of sigma ligands in opioid-induced hyperalgesia |
| 06/12/2013 | EP2600862A2 Inhibitors of erk for developmental disorders of neuronal connectivity |
| 06/12/2013 | EP2600861A1 Use of teriflunomide for treating multiple sclerosis |
| 06/12/2013 | EP2600860A1 Substituted 2-hydroxy-4-(2-(phenylsulfonamido)acetamido)benzoic acid analogs as inhibitors of stat proteins |
| 06/12/2013 | EP2600859A1 Combinations of beta - 3 adrenergic receptor agonists and muscarinic receptor antagonists for treating overactive bladder |
| 06/12/2013 | EP2600858A2 Supramolecular complexes of polyanionic polymers and spermidine in tissue maintenance and repair |
| 06/12/2013 | EP2600857A2 Treatment of mitochondrial diseases with naphthoquinones |
| 06/12/2013 | EP2600856A1 Composition comprising retinol, a precursor or a reaction product of it and a plant extract from at least one chamomilla plant for the treatment of cancer |
| 06/12/2013 | EP2600855A2 Combination therapy for the treatment of prostate carcinoma |
| 06/12/2013 | EP2600854A1 Phenethyl, phenethylene, phenethyne and indanone derivates in cosmetic formulations, especially for use in skin ageing processes |
| 06/12/2013 | EP2600853A1 Combinations comprising atypical antipsychotics and taar1 agonists |
| 06/12/2013 | EP2600852A2 Beclomethasone dipropionate compositions in modified-release gastro-resistant microspheres and process for obtaining them |
| 06/12/2013 | EP2600851A2 Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine for the treatment of neuropathic pain |
| 06/12/2013 | EP2600850A2 Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine for the treatment of nociceptive pain |
| 06/12/2013 | EP2600847A1 Oral pharmaceutical formulations of esomeprazole in the form of mups (multi unit pellets system) tablets |
| 06/12/2013 | EP2600846A2 Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cylohexane-1,1'-pyrano[3,4,b]indol]-4-amine |
| 06/12/2013 | EP2600844A2 Interior functionalized hyperbranched dendron-conjugated nanoparticles and uses thereof |
| 06/12/2013 | EP2600842A1 Microparticle formulation for pulmonary drug delivery of anti-infective molecule for treatment of infectious diseases |
| 06/12/2013 | EP2600841A2 Pharmaceutical formulations of rasagiline |
| 06/12/2013 | EP2600839A2 Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4,9'-dihydro-3'h-spiro[cylohexane-1,1'-pyrano[3,4,b]indol]-4-amine |
| 06/12/2013 | EP2600838A2 Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine |
| 06/12/2013 | EP2600837A1 Use of glyceryl trinitrate for treating hematomas |
| 06/12/2013 | EP2600835A1 Combinations of hepatitis c virus inhibitors |
| 06/12/2013 | EP2600832A1 Combination of compounds for treating or preventing skin diseases |
| 06/12/2013 | EP2600831A2 Oral dosage form of pregabalin |
| 06/12/2013 | EP2600830A2 Dry powder formulation comprising a phosphodiesterase inhibitor |
| 06/12/2013 | EP2600829A2 Pharmaceutical formulation comprising a phosphodiesterase inhibitor |
| 06/12/2013 | EP2600792A1 Devices, systems, and methods for excavating cancer cells |
| 06/12/2013 | EP2600719A1 2-substituted-8-alkyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitriles and uses thereof |
| 06/12/2013 | EP2600716A1 Methods and compositions for treatment of metabolic disorders |
| 06/12/2013 | EP2600715A1 St-246 liquid formulations and methods |
| 06/12/2013 | EP2475657B1 5-alkinylthien-2-ylcarboxylic acids as inhibitors of flaviviridae viruses |
| 06/12/2013 | EP2178869B1 Indole compounds as an inhibitor of cellular necrosis |
| 06/12/2013 | CN1980710B Substituted azepine derivatives as serotonin receptor modulators |
| 06/12/2013 | CN1943577B Use of (2-imidazolin-2-ylamino) quinoxalines in treating ocular neural injury |
| 06/12/2013 | CN1942588B Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
| 06/12/2013 | CN1922332B Methods for predicting and overcoming resistance to chemotherapy in ovarian cancer and for predicting colon cancer occurrence |
| 06/12/2013 | CN1921885B Method of regulating phosphorylation of sr protein and antiviral agents comprising sr protein activity regulator as the active ingredient |
| 06/12/2013 | CN1917922B Use of substituted 1,2,3 indolizine derivatives in the preparation of medicaments which can be used to treat diseases linked to pathological choroidal angiogenesis |
| 06/12/2013 | CN1917886B Core 2 glcnac-t inhibitors |
| 06/12/2013 | CN1854135B Heteronuclear compound with dicyandiamide connection and its medicinal use |